Disease · MONDO_0011122
Comparisons in its trials224
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 224
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Sema 2.4 mg vs Placebo: deaths from any cause | 1 of 1,306 | 1 of 655 | 1,961 | NCT03548935 | Trial comparisons |
| Sema 2.4 mg vs Placebo: serious adverse events | 128 of 1,306 | 42 of 655 | 1,961 | NCT03548935 | Trial comparisons |
| NB32/48 vs Placebo: serious adverse events | 21 of 992 | 7 of 492 | 1,484 | NCT00567255 | Trial comparisons |
| NB32 vs Placebo: serious adverse events | 22 of 584 | 1 of 200 | 784 | NCT00456521 | Trial comparisons |
| 15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide: deaths from any cause | 0 of 374 | 0 of 376 | 750 | NCT05822830 | Trial comparisons |
| 15 mg or MTD - Tirzepatide vs 2.4 mg or MTD - Semaglutide: serious adverse events | 18 of 374 | 13 of 376 | 750 | NCT05822830 | Trial comparisons |
| Tirzepatide - MTD vs Placebo: Number of Participants With Time to All-Cause Death | 19 of 364 | 15 of 367 | 731 | NCT04847557 | Trial comparisons |
| Tirzepatide - MTD vs Placebo: Number of Participants With Time to First Occurrence of HF Events | 29 of 364 | 52 of 367 | 731 | NCT04847557 | Trial comparisons |
| Tirzepatide - MTD vs Placebo: deaths from any cause | 19 of 364 | 15 of 367 | 731 | NCT04847557 | Trial comparisons |
| Tirzepatide - MTD vs Placebo: serious adverse events | 96 of 364 | 94 of 367 | 731 | NCT04847557 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: deaths from any cause | 0 of 407 | 0 of 204 | 611 | NCT03611582 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: serious adverse events | 37 of 407 | 6 of 204 | 611 | NCT03611582 | Trial comparisons |
| Tirzepatide vs Placebo: deaths from any cause | 1 of 287 | 1 of 292 | 579 | NCT04657016 | Trial comparisons |
| Tirzepatide vs Placebo: serious adverse events | 17 of 287 | 14 of 292 | 579 | NCT04657016 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: deaths from any cause | 3 of 263 | 4 of 266 | 529 | NCT04788511 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: serious adverse events | 35 of 263 | 71 of 266 | 529 | NCT04788511 | Trial comparisons |
| NB32 vs Placebo: serious adverse events | 13 of 333 | 8 of 169 | 502 | NCT00474630 | Trial comparisons |
| Lira 3.0 mg vs Placebo: serious adverse events | 9 of 212 | 5 of 210 | 422 | NCT00781937 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: deaths from any cause | 0 of 269 | 0 of 135 | 404 | NCT05064735 | Trial comparisons |
| Semaglutide 2.4 mg vs Placebo: serious adverse events | 27 of 269 | 11 of 135 | 404 | NCT05064735 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0011122/comparisons